Literature DB >> 1083263

Granulopoiesis in severe congenital neutropenia.

D Amato, M H Freedman, E F Saunders.   

Abstract

The pathogenesis of the granulopoietic failure in three children with severe congenital neutropenia was studied. Mature neutrophils were absent from both peripheral blood and bone marrow. Assay of bone marrow granulocyte colony-forming cells (CFU-C) in a methylcellulose tissue culture system using colony-stimulating activity (CSA) from peripheral blood leukocytes demonstrated normal or increased concentrations of CFU-C compared to those from marrows of 60 age-matched controls. Colonies were of normal size and by light microscopy appeared to contain granulocytes in all stages of maturation including the mature polymorphonuclear neutrophil. CFU-C from peripheral blood of two patients were normal. Production and activity of CSA from the patients' peripheral blood leukocytes and urinary CSA excretion were normal. No serum inhibitors against CFU-C or CSA could be demonstrated using both control and autologous marrow. The defect did not appear to be due to a lack of granulocytic stem cells, a reduction of humoral stimulators of granulopoiesis, nor the presence of an inhibitor as measured by these techniques.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1083263

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

1.  Selective protection of tubercidin toxicity by nitrobenzyl thioinosine in normal tissues but not in human neuroblastoma cells.

Authors:  C Kaplinsky; H Yeger; Z Estrov; J Barankiewicz; G Pawlin; M H Freedman; A Cohen
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment.

Authors:  A C Ward; Y M van Aesch; J Gits; A M Schelen; J P de Koning; D van Leeuwen; M H Freedman; I P Touw
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.